Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00156689 · ClinicalTrials.gov registry record · Phase 2
A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.
A Phase 2 study of Chronic Idiopathic Axonal Polyneuropathy, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00156689 is a Phase 2 study of Chronic Idiopathic Axonal Polyneuropathy that has completed, run by Vanderbilt University. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00156689, a Phase 2 study of Chronic Idiopathic Axonal Polyneuropathy, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Considering the mechanisms of action which provide efficacy in epilepsy, it is hypothesized that treatment with levetiracetam will reduce the neuronal excitability involved in neuropathic pain associated with CIAP. Thus, there is a potential for levetiracetam to bring therapeutic benefit for the subjects because of its specific mechanism of action, its safety profile and the absence of interaction with other drugs.
Conditions Studied
Interventions
- DRUG levetiracetam
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00156689
The ClinicalTrials.gov registry entry for NCT00156689 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Idiopathic Axonal Polyneuropathy appearing as the primary indexed condition, and to 1 intervention - of which levetiracetam is the first listed.
NCT00156689 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00156689 about?
NCT00156689 is a clinical study titled "A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.". Considering the mechanisms of action which provide efficacy in epilepsy, it is hypothesized that treatment with levetiracetam will reduce the neuronal excitability involved in neuropathic pain associated with CIAP. Thus, there is a potential for levetiracetam to bring therapeutic benefit for the sub...
What is the current status of trial NCT00156689?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-08. Estimated completion is 2007-05.
What conditions does trial NCT00156689 study?
This clinical trial studies the following conditions: Chronic Idiopathic Axonal Polyneuropathy.
What interventions are being tested in trial NCT00156689?
The interventions under investigation include: levetiracetam (DRUG).
Who is sponsoring clinical trial NCT00156689?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00156689 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.